

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

NCT06284577

Status	RECRUITING
Phase	Not Applicable
Sponsor	Oslo University Hospital
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (6)

- CFTR mutations eligible for treatment with ETI
- Age 2-18 years. Majority of patients will be 2-6 years of age as ETI was approved from 6 years of age in 2022, and will be available for children above 2 years from 2024.
- Included in the Norwegian CF Register and consented to participation in CF general research biobank
- Age 3-18 years
- CFTR modulator treatment naïve or treated with CFTR modulator for at least 6 months
- ... and 1 more (see full listing online)

Exclusion (6)

- Other CFTR modulators commenced the last 6 months before inclusion
- Use of probiotics or prebiotics last 2 months
- Current pulmonary exacerbation
- CFTR modulators commenced the last 6 months before inclusion
- Use of probiotics or prebiotics last 2 months
- ... and 1 more (see full listing online)

Locations (1 total)

Oslo University Hospital, Oslo, Norway